A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

NCT06421636 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Transfusion Dependent Beta-Thalassemia (NTDT)

Interventions

DRUG: REGN7999
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals